It's truism in spine that 4% of patients rack up 75% in costs, and expensive BMP products, which are highly successful at enhancing fusion rates, are the "high octane" products for more difficult cases-high-risk patients or the obese, for example. The market needs a product for the majority of cases, believes the founder of CeraPedics LLC, and he believes his company has it in its P-15, a growth factor that's a small peptide.
12860 West Cedar Drive, Suite 101
Lakewood, CO 80228
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.
The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.
The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.
Comes Days After PDUFA Pushback For GSK's Blenrep.
A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.
The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.
Comes Days After PDUFA Pushback For GSK's Blenrep.
